Sitagliptin: New Oral Antidiabetic Agent for Tip 2 Diabetes Mellitus

Yıl 2011, Cilt: 11 Sayı: 2, 1 - 13, 01.08.2011

Ömer Hazman

Öz

Anahtar Kelimeler

-

Sitagliptin: Tip 2 Diyabet Tedavisi için Yeni Oral Antidiyabetik Ajan

Öz

Tip 2 Diyabet (T2DM) dünya genelinde yaygın ve hastalar hatta toplum için önemli sonuçları olan bir epidemik bir hastalıktır. T2DM için mevcut tedavi yöntemlerinin doza bağlı sınırlamaları ve yan etkileri (kilo artışı, hipoglisemi ve sindirim sistemi problemleri gibi) olduğu için, yeni tedavi seçeneklerine ihtiyaç duyulmaktadır. Bu yüzden sitagliptin gibi dipeptidil peptidaz-4 (DPP 4) inhibitörleri olarak adlandırılan yeni bir yaklaşım geliştirilmiştir. Sitagliptinle DPP 4 inhibisyonu, glukagon-like peptid-1 (GLP-1)’in aktivasyonunu engelleyerek insülin sekresyonunu artırır, glukagon sekresyonunu azaltır ve böylelikle kan glukoz seviyeleri dengelenir. Yapılan birçok çalışma göstermektedir ki sitagliptin hastaların kilo almalarını önleyerek ve hipoglisemi riskini azaltarak, güvenilir, tolare edilebilir bir ilaç profili çizmektedir. Bununla birlikte in vitro çalışmalarda sitagliptinin pankreatik beta hücre kütlesini artırdığı ve beta hücre fonksiyonlarını koruduğu gösterilmiştir. Tip 2 diyabet tedavisinde sitagliptin tek başına veya diğer oral antidiyabetiklerle combine tedavi şeklinde kullanılabilir. Bu makalede, yapılan en son araştırmalar incelenerek sitagliptinin T2DM hastalarında glisemik kontrolü sağlamadaki etkinliği ve diyabetik komplikasyonlara etkisi tartışılacaktır.

Anahtar Kelimeler

Sitagliptin, DPP 4 inhitörleri, tip 2 diyabet, diyabetik komplikasyonlar.

Kaynakça

• Ahren B., Holst J., Martensson H., Balkan B., 2000. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice, Eur J Pharmacol, 404, 239-45.
• Ahren B., 2007. DPP-4 inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism, 21(4), 517-533.
• Aschner P., Katzeff H.L., Guo H., Sunga S., Williams- Herman D., Kaufman KD., Goldstein B.J., 2010. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes, Diabetes, Obesity and Metabolism, 12, 252–261.
• Aschner P., Kıpnes M.S., Lunceford J.K., Sanchez M., Mıckel C., Wıllıams-Herman D.E., 2006, Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes, Diabetes Care, 29, 2632–2637.
• Barnet A., 2006, DPP-4 inhibitors and their potential role in the management of type 2 diabetes, Int. J. Clin. Pract, 60(11), 1454-1470.
• Başkal N., 2007. Diyabet Tedavisinde Yeni Açılımlar. Endokrinolojide Diyalog, 4 (Özel Sayı), 215-222.
• Baxter M., 2008. Treatmant of Type 2 Diabetes: a Structured Management Plan. Adv. Ther., 25(2), 106- 114.
• Bergman A.J., Stevens C., Zhou Y.Y., Yi B., Laethem M., De Smet M., Snyder K., Hilliarcl D., Tanaka W., Zeng W., Tanen M., Wang E.Q., Chen L., Winchell G., Davies M.J., Ramael S., Wagner J.A., Herman G.A., 2006. Pharmacokinetic and Pharmacodynamic Properties of Multiple Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Double-Blind, Randomized, Placebo-Controlled Study in healthy male Volunteers, Clinical Therapeutics, 28(1), 55-72.
• Buteau J., 2008. GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival, Diabetes & Metabolism, 34, 73-77.
• Creutzfeldt W., 2005. The [pre-] history of the incretin concept, Regul. Pept, 128, 87-91.
• D’Amico M., Filippo C.D., Marfella R., Abbatecola A.M., Ferraraccio F., Rossi F., Paolisso G., 2010. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice, Experimental Gerontology, 45, 202-207.
• Deacon C.F., 2007. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes, Expert Opin. Investig. Drugs, 16, 533–545.
• Deacon C.F., 2005. What do we know about the secretion and degradation of incretin hormones?, Regul Pept., 128, 117-124.
• Delibaş N., Kılınç İ., 2003. İnsulin ve Gliklazid Tedavisinin Streptozotosin Diabetik Rat Hipokampüslerinde Lipid Peroksidasyonuna Etkisi, Türk Biyokimya Klinik Dergisi, 1(1), 33-39.
• Derosa D., Maffiolia P., Sibilla A.T., Ferraria I., Ragonesib P.D., Quercic F., Franzettid I.G., Gadaletae G., Ciccarellif L., Piccinnig M.N., D'Angeloa A., Arrigo F.G., 2010. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients, Metabolism Clinical and Experimental, 59, 887–895.
• Dore D.D., Seeger J.D., Arnold Chan K., 2009. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide, Curr Med Res Opin., 25(4), 1019-27.
• Doupis J., 2008. DPP4 İnhibitors: a New Approach in Diabetes Treatment, Adv. Ther, 25 (7), 627-643.
• Garber A.J., 2008. Glucagon like peptide 1 based therapies: new developments and emerging data, Diabetes, Obesity and Metabolism, 10 (suppl. 3), 22- 35.
• Halimi S., 2008. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?, Diabetes & Metabolism, 34, 91-95.
• Hanefeld M, Herman GA, Wu M et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2diabetes. CurrMedRes Opin. 2007; 23:1329–1339.
• Hazman Ö., 2011. Oral antidiyabetik ilaç Sitagliptin’in oksidan-antioksidan denge üzerine etkisinin deneysel tip araştırılması”, Biyokimya Anabilim Dalı (Vet.), Doktora Tezi, Afyon Kocatepe Üniversitesi Sağlık Bilimleri Enstitüsü oluşturulan ratlarda
• Hazman Ö., Çelik S., 2011, Tip 2 Diyabetli Ratlarda Sitagliptinin Oksidatif Stres Üzerine Etkisi”, V.Ulusal Veteriner Biyokimya ve Klinik Biyokimya Kongresi, AYDIN, 6-8 Eylül, S21.
• Herman G., Hanefeld M., Wu M., Chen X., Zhao P., Stein P., 2005. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with T2DM, Diabetes, 54 (suppl 1), A134.
• Hermansen K., Kipnes M., Luo E., Fanurik D., Khatamani H., Stein P., 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, Diabetes Obes Metab, 9, 733–745.
• Jabbour S.A., Goldstein B. J., 2008. Sodium glucose co- transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes, Int J Clin Pract, 62, 8, 1279–1284.
• James M., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., Thornberry N.A., Zhang B.B., 2006. Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes, Diabetes, 55, 1695-1704.
• Kavak S., 2008. Roziglitazonun Diyabetik Sıçan Papiller Kalp Kasının Mekanik ve Elektriksel Aktiviteleri Üzerine Etkisi (Doktora Tezi), Çukurova Üniversitesi Sağlık Bilimleri Enstitüsü Biyofizik Anabilim Dalı, Adana
• Kurt İ., 2003. Glikozile hemoglobin(HbA1c) ölçümü ve diabetes kontrolünde kullanılması. Gülhane Tıp Dergisi, 45 (4), 387-395. uzun dönem glisemik
• Liu X., Harada N., Yamane S.,Kitajima L., Uchida S.,Hamasaki A., Mukai E., Toyoda K., Yamada C., Yamada Y., Seino Y., Inagaki N., 2009., Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet- fed mice, Life Sciences, 84, 876–881.
• Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I., Cremasco F., Ognibene A., Rotella C.M., 2005. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus, Diabetologia 48, 1168– 1172.
• Matveyenko A.V., Dry S., Cox H.I., Moshtaghian A., Gurlo T., Galasso R., Butler A.E., Butler P.C., 2009. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin, Diabetes, 58(7), 1604-1615.
• McIntosh C., Demuth H., Pospisilik J., Pederson R., 2005. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, Regulatory Peptides, 128:159-65.
• McKennon S.A., Campbell R.K., 2007. The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors, Diabetes Educator, 33, 55–66.
• Meester I.D., Durinx C., Bal G., Proost P., Struyf S., Goossens F., Augustyns K., Scharpé S., 2000. Natural substrates of dipeptidyl peptidase IV, Adv. Exp. Med. Biol., 477, 67-87.
• Mentlein R., 1999. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides, Regul Pept., 85, 9-24.
• Miller S.A, Onge E.L., 2006. Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes, Ann Pharmacother, 40, 1336-43.
• Mistry, G. C., Bergman, A. J., Zheng,W., Hreniuk, D., Gottesdiener, Zinny,M. J.A., Herman G.A., Ruddy M., 2008. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects, Br. J. Clin. Pharmacol, 66, 36–42.
• Mohan V.,Yang W., Son HY., Xu L., Noble L., Langdon R.B., Amatruda J.M., Stein P.P., Kaufman K.D., 2009. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea, Diabetes Research and Clinical Practice, 83, 106–116.
• Mu J., Petrov A., Eiermann GJ., Woods J., Zhou YP., Li Z., Zycband E., Feng Y., Zhu L., Roy RS., Howard AD., Li C., Thornberry NA., Zhang BB., 2009. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes, European Journal of Pharmacology, 623(1-3), 148-54.
• Nathan D.M., Buse J.B., Davidson M.B. et all. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm fort he initiation and adjustment. Diabetologia, 51, 8-11
• Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P., 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabetes, Obesity & Metabolism, 9, 194–205.
• Nonaka K., Kakikawa T., Sato A., Okuyama K., Fujimoto G., Kato N., Suzuki H., Hirayama Y., Ahmed T., Davies M.J., Stein P.P., 2008. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes, Diabetes Research and Clinical Practice, 79, 291–298. Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., Langdon R.B., Stein P.P., Alba M., 2008. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients, with type 2 diabetes, Curr Med Res Opin., 24:537–550.
• Raz I., Hanefeld M., Xu L., Caria C., 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus, Diabetologia, 49, 2564-2571.
• Rosenstock J., Brazg R., Andryuk P.J., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, parallel-group study, Clin Ther, 28(10), 1556–1568.
• Ryskjaer J., Deacon C.F., Carr R.D., Krarup T., Madsbad S., Holst J., Vilsboll T., 2006. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake, Eur JEndocrinol, 155, 485–493,
• Scott R., Herman G., Zhao P., Chen X., Wu M., Stein P., 2005. Twelve-week efficacy and tolerability of MK- 0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of T2DM (T2D) (abstract 41-OR), Diabetes, 54(suppl 1), A10-11.
• Scott R., Loeys T., Davies M.J., Engel SS., 2007. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 10, 959–969. Turkdiab.org, 2011, page.aspx?u=4&s=49 , 21.10.2011.
• http://www.turkdiab.org/
• Ükinç K., Gürlek A. Umsan A., 2007. Yeni Antidiyabetik İlaçlar. Hacettepe Tıp Dergisi, Cilt 38, Sayı 3, 113-120.
• UKPDS Group, United Kingdom Prospective Diabetes Study Group, (1995) U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease, Diabetes, 44, (11), 1249-1258.
• Xu L., Man C.D., Charbonnel B., Meninger G., Davies M.J., Williams-Herman D., Cobelli C., Stein P.P., 2008. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach, Diabetes, Obesity and Metabolism, 10, 1212–1220.
• Verspohl E.J., 2009, Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 peptidase-4 Therapeutics, 124, 113–138. and Pharmacology inhibitors, &
• Vilsbell T., 2008. Initial combination therapy with sitagliptin, a dipeptidyl peptidase 4 inhibitöor and metformin for patients with type 2 diabetes mellitus, Expert. Rev. Endocrinaol. Metab., 3, 13-19. Vilsbİll T., Rosenstock
• J., Yki-Järvinen H., Cefalu
• W.T., Chen Y., Luo E., Musser B., Andryuk P.J., Ling
• Y., Kaufman K.D., Amatruda J.M., Engel S.S., Katz L.,
• Efficacy and safety of sitagliptin when added to
• insulin therapy in patients with type 2 diabetes,
• Diabetes, Obesity and Metabolism, 12, 167–177, 2010.
• Vilsboll T., Krarup T., Deacon C., Madsbad S., Holst J., 2001. Reduced postprandial concentrations of intact biologically active glucagons-like peptide 1in type 2 diabetic patients, Diabetes, 50. 609-13.
• Williams-Herman D., Johnson J., Teng R., Luo E., Davies MJ., Kaufman KD., Goldstein BJ., Amatruda JM., 2009. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study, Curr. Med. Res. Opin., 25(3), 569-83.
• Yu B., Wang A., 2008. Glukagon-like peptide 1 based therapy for type 2 diabetes. World J. Pediatr., 4(1), 8- 13.
• Ye Y., Keyes K.T., Zhang C., Perez-Polo J.R., Lin Y., Birnbaum Y., 2010. The myocardial infarct size limiting effects of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA, Am J Physiol Heart Circ Physiol., 298(5), H1454-65.
• Vaghasiya J., Sheth N, Bhalodia Y, Manek R, 2011, Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes, Regulatory Peptides, 166, 48–54
• Tan L., Tan S., 2008. Sitagliptin Decreases C-reactive Protein, Monocyte Chemotactic Protein-1, Myloperoxidase activity, and Interleukin-6 in Diabetics with atherosclerosis, Journal of Clinical Lipidology, 2, 5S.